Marshall Wace
ANIP icon

Marshall Wace’s ANI Pharmaceuticals ANIP Stock Holding History

Marshall Wace’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,518
Closed -$436K – 3163
2025
Q4 		$436K Sell
5,518
-24,674
-82% -$2.14M ﹤0.01% 2294
2025
Q3 		$2.77M Buy
+30,192
New +$2.46M ﹤0.01% 1463
2024
Q3 		– Sell
-3,979
Closed -$253K – 2468
2024
Q2 		$253K Buy
+3,979
New +$258K ﹤0.01% 2221
2023
Q4 		– Sell
-89,093
Closed -$5.17M – 2146
2023
Q3 		$5.17M Buy
89,093
+78,847
+770% +$4.55M 0.01% 851
2023
Q2 		$552K Sell
10,246
-953
-9% -$42.2K ﹤0.01% 1949
2023
Q1 		$445K Buy
+11,199
New +$472K ﹤0.01% 2149
2022
Q1 		– Sell
-44,600
Closed -$2.06M – 3310
2021
Q4 		$2.06M Buy
+44,600
New +$1.92M ﹤0.01% 2024
2019
Q2 		– Sell
-11,303
Closed -$797K – 1326
2019
Q1 		$797K Buy
+11,303
New +$665K 0.01% 1009
2018
Q4 		– Sell
-9,289
Closed -$525K – 1571
2018
Q3 		$525K Buy
+9,289
New +$568K ﹤0.01% 915

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace's ANIP Position: Q1 2026 in Review

Marshall Wace sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 5,518 shares — an estimated $436K sold.

Marshall Wace first reported a position in ANIP in Q3 2018 and held it in 9 quarters. The position peaked at $5.17M in Q3 2023. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Marshall Wace reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 5,518 ANI Pharmaceuticals shares in Q1 2026, an estimated $436K.
  • Marshall Wace first reported a position in ANI Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Marshall Wace's ANI Pharmaceuticals position peaked at $5.17M in Q3 2023.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.